Docetaxel/Carboplatin is named as an intervention in 2 current clinical trials in our China and Japan registers. 2 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Shanghai Jiao Tong University School of Medicine (1). The most-studied condition is Recurrent Non-small Cell Lung Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03919552 · ClinicalTrials.gov ↗ · Cisplatin, Carboplatin, NPC
|
Phase 3 | Recruiting | Nanfang Hospital, Southern Medical University | China |
|
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
NCT02889666 · ClinicalTrials.gov ↗ · Recurrent Non-small Cell Lung Cancer
|
Phase 1 | Recruiting | Shanghai Jiao Tong University School of Medicine | China, Japan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai Jiao Tong University School of Medicine | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
| Clinical trials in Japan | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and Japan registers name Docetaxel/Carboplatin as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shanghai Jiao Tong University School of Medicine (1) and Nanfang Hospital, Southern Medical University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Docetaxel/Carboplatin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Docetaxel/Carboplatin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Docetaxel/Carboplatin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.